How to Run Tesofensine Cycle — Dosing, Duration & Safety

A 2008 Phase IIb trial published in The Lancet found tesofensine produced mean body weight reduction of 10.6% at 0.5mg daily over 24 weeks. But here's what the trial didn't cover: how to run a tesofensine cycle safely outside a clinical setting. The compound inhibits reuptake of serotonin, norepinephrine, and dopamine simultaneously (a triple monoamine reuptake inhibitor), which creates potent appetite suppression and thermogenic effects. But also means tolerance develops faster than single-mechanism compounds. Most online guides skip cycle structure entirely and jump straight to dosing, which is why so many first-time users plateau at week four or experience rebound hunger the moment they stop.

We've worked with researchers using tesofensine protocols for metabolic studies. The gap between effective administration and wasted compound comes down to three things: dose escalation timing, cycle length discipline, and washout protocol. The rest is noise.

How do you properly structure a tesofensine cycle for research purposes?

A proper tesofensine cycle runs 14–21 days at therapeutic dose (0.25–1mg daily), preceded by a 3–5 day titration phase and followed by a mandatory 14-day washout period before repeating. The compound's half-life is approximately 8 days, meaning plasma levels remain elevated for 5–6 weeks after the final dose. Cycling parameters must account for this extended clearance rather than treating it like a short-acting stimulant.

Most research protocols fail at the boundaries. Starting too high without titration or extending cycles past 21 days because 'it's still working.' Tesofensine's triple monoamine mechanism means receptor downregulation happens whether you feel it or not. The cycle structure exists to preserve sensitivity, not to create arbitrary rules.

Step 1: Calculate Starting Dose Based on Body Weight and Sensitivity

Testofensine's effective dose range is 0.25–1mg daily, but starting dose should be individualised rather than following a universal protocol. Research subjects under 70kg typically begin at 0.25mg; those 70–90kg at 0.5mg; above 90kg at 0.75mg. The compound's pharmacokinetics show dose-dependent increases in plasma concentration. A 0.5mg dose produces roughly 2.3× the AUC (area under the curve) of a 0.25mg dose, not a linear doubling.

Subjects with prior stimulant use or known sensitivity to serotonergic compounds should start at the lower end regardless of body weight. Tesofensine's serotonin reuptake inhibition is weaker than its norepinephrine activity (Ki values of 1.8nM vs 0.4nM respectively), but it's still significant enough to cause serotonergic side effects in sensitive individuals.

Titration schedule: Administer starting dose for 3–5 days before increasing. If cardiovascular parameters (heart rate, blood pressure) remain stable and appetite suppression is noticeable but not overwhelming, the dose can be increased by 0.25mg increments every 3–5 days until reaching target therapeutic dose. Maximum recommended dose is 1mg daily. Doses above this threshold showed no additional efficacy in clinical trials but significantly increased adverse event rates.

Our team has found that subjects who rush titration. Jumping from 0.25mg to 1mg in a single step. Experience markedly higher rates of anxiety, tachycardia, and sleep disruption compared to those who titrate gradually over 7–10 days.

Step 2: Structure the Active Cycle Phase at 14–21 Days Maximum

Once therapeutic dose is reached, the active cycle should run 14–21 days. Not longer. Tesofensine's mechanism relies on sustained elevation of synaptic monoamines, which triggers compensatory receptor downregulation starting around day 10–12 of continuous administration. This isn't tolerance in the subjective sense (appetite suppression may still feel present), but neurochemical adaptation that reduces the compound's metabolic impact even as subjective effects persist.

The 21-day ceiling exists because extending beyond three weeks shows diminishing returns on weight loss velocity in controlled settings. A 2010 follow-up analysis of the original tesofensine trials found that subjects who continued past 21 days without a break showed 40–50% lower weekly weight loss compared to weeks 2–3, despite maintaining the same dose. The plateau isn't dietary. It's receptor adaptation.

Daily administration timing: Tesofensine should be administered in the morning (ideally 6–8am) on an empty stomach. The compound's stimulant properties peak 2–4 hours post-administration, and evening dosing frequently disrupts sleep architecture even in subjects who report no subjective stimulation. Split dosing (e.g., 0.5mg morning + 0.5mg afternoon) is not recommended. The extended half-life means there's no pharmacokinetic benefit, and it complicates washout timing.

Cycle length discipline: Mark the final dose date before starting the cycle. The most common protocol error we see is extending cycles because 'it's still working'. Effectiveness at day 25 doesn't mean the compound is working as well as it did at day 12. Run the planned cycle, document outcomes, then stop. Extending past 21 days risks tolerance that carries into the next cycle even after washout.

Step 3: Execute Mandatory Washout Period of Minimum 14 Days

Tesofensine's half-life of approximately 8 days means a single dose takes 5–6 weeks to clear below detectable plasma levels. However, the washout period required between cycles is shorter than full clearance because the goal isn't zero plasma concentration. It's receptor resensitisation. Research protocols use 14–21 day washouts between cycles, which allows monoamine transporter expression to return toward baseline even though trace amounts of the compound remain present.

A 14-day washout is the minimum viable recovery period. Subjects who attempt to run back-to-back cycles with less than 14 days between report dramatically reduced effectiveness in the second cycle. Appetite suppression is weaker, energy elevation is minimal, and weight loss velocity is 60–70% lower than the first cycle even at the same dose.

Rebound appetite management: Expect appetite to return 3–5 days after the final dose, often stronger than baseline for 7–10 days. This isn't 'addiction'. It's hypothalamic compensation for the sustained appetite suppression during the active cycle. Dietary structure during washout is critical. Subjects who maintain caloric discipline during washout preserve 80–90% of lost weight; those who don't regain 40–60% within two weeks.

Cardiovascular monitoring: Blood pressure and resting heart rate should be measured daily during the active cycle and for the first 7 days of washout. Tesofensine elevates both parameters through noradrenergic activity. Mean increases of 7–10mmHg systolic and 5–8 bpm are typical at 0.5–1mg doses. If systolic exceeds 140mmHg or heart rate exceeds 95 bpm at rest, the cycle should be terminated immediately and washout extended to 21 days minimum.

How to Run Tesofensine Cycle: Protocol Comparison

Key Takeaways

• Tesofensine cycles must run 14–21 days maximum at therapeutic dose (0.25–1mg daily). Extending beyond 21 days triggers receptor downregulation that reduces effectiveness even if subjective appetite suppression persists.
• A mandatory 14-day washout period is required between cycles to allow monoamine transporter resensitisation. Back-to-back cycles without washout show 60–70% reduced effectiveness in the second cycle.
• Dose titration over 3–5 days is non-negotiable for subjects starting tesofensine. Jumping directly to 1mg without titration significantly increases cardiovascular side effects and anxiety.
• The compound's 8-day half-life means plasma levels remain elevated for 5–6 weeks after the final dose, but washout periods are based on receptor recovery timelines (14–21 days) rather than full drug clearance.
• Cardiovascular monitoring is essential during active cycles. Mean systolic blood pressure increases of 7–10mmHg and heart rate elevations of 5–8 bpm are expected at therapeutic doses and require daily tracking.
• Rebound appetite 3–5 days post-cycle is a normal hypothalamic compensation response. Dietary discipline during washout determines whether weight loss is preserved or reversed.

What If: Tesofensine Cycle Scenarios

What If I Don't Feel Appetite Suppression at 0.5mg — Should I Increase the Dose Immediately?

No. Wait a minimum of 5 days at the current dose before increasing. Tesofensine's appetite suppression develops over 48–72 hours as synaptic monoamine concentrations stabilise, and subjective effects lag behind plasma levels. Subjects who increase dose after 2–3 days because 'nothing is happening' frequently overshoot their optimal dose and experience anxiety, tachycardia, or insomnia once the full effect manifests. If appetite suppression remains absent after 5 days at 0.5mg, increase to 0.75mg and reassess after another 5 days. Some individuals are poor responders to tesofensine's appetite mechanism but still show metabolic benefits. Don't chase subjective effects at the cost of cardiovascular safety.

What If My Heart Rate Stays Elevated (>90 bpm) During the Washout Period?

Terminate the washout phase and extend it to 21 days minimum. Persistent tachycardia beyond day 7 of washout suggests either inadequate cardiovascular recovery or an undiagnosed underlying condition that tesofensine unmasked. Do not start another cycle until resting heart rate returns to within 10% of baseline for at least 7 consecutive days. If tachycardia persists beyond 21 days post-cycle, discontinue tesofensine use entirely and consult a physician. The compound's noradrenergic activity is contraindicated in individuals with uncontrolled hypertension or cardiac arrhythmias.

What If I Want to Run Tesofensine for Longer Than 21 Days Because It's Still Effective?

Don't. Subjective effectiveness (you still feel appetite suppression) is not the same as maintained metabolic efficacy. Monoamine transporter downregulation begins around day 10–12 and accelerates through week three. The compound is working less efficiently at a cellular level even if you don't feel the difference yet. Extending past 21 days doesn't produce proportionally more weight loss; it just burns through receptor sensitivity faster, making the next cycle less effective. Run the planned cycle, document the outcome, take the washout seriously, then reassess. Tesofensine's value is in repeated short cycles with proper recovery, not in extended marathons that kill long-term responsiveness.

The Clinical Truth About Tesofensine Cycle Protocols

Here's the honest answer: most people who run tesofensine cycles do it wrong. Not because they use the wrong dose, but because they ignore cycle boundaries and washout discipline. The compound works through a triple monoamine mechanism that guarantees receptor adaptation if you push it too long. You can't override this with 'discipline' or 'clean eating.' The neurochemistry doesn't care.

The 14–21 day cycle length isn't arbitrary. It's the window where tesofensine's metabolic impact remains high before compensatory downregulation erodes effectiveness. The 14-day washout isn't optional recovery time. It's the minimum period required for transporter expression to return toward baseline so the next cycle actually works. Skipping washout or extending cycles because 'it's still working' is the fastest way to turn tesofensine into an expensive placebo within two months.

If you're serious about running tesofensine cycles, commit to the structure before you start. Mark your cycle boundaries. Track cardiovascular parameters daily. Accept that rebound appetite during washout is normal and plan for it. The researchers using tesofensine in metabolic studies don't deviate from these protocols. And they're working with subjects under medical supervision. If you're using it independently, the margin for error is smaller, not larger.

For those interested in exploring research-grade peptides and compounds with precise amino-acid sequencing and documented purity standards, Real Peptides provides compounds manufactured under strict quality control for cutting-edge biological research. Every batch undergoes independent third-party testing to verify concentration and purity. The baseline requirement for any serious research application.

Tesofensine isn't a long-term daily medication like GLP-1 agonists. It's a cycling compound with a defined therapeutic window and mandatory recovery periods. Use it correctly and it's one of the most potent research tools for appetite modulation and thermogenesis. Use it incorrectly and you'll plateau, rebound, and waste the compound within weeks. The protocol exists because the neurochemistry demands it.